Breaking Finance News

A statement released earlier today by Numis about BTG PLC (LON:BTG) maintains the target price at 737.00GBX

Numis hold steady the target of BTG PLC (LON:BTG) at 737.00GBX stating a potential upside of 0.08%.

Yesterday BTG PLC (LON:BTG) traded 2.56% higher at 682.75GBX. The company’s 50-day moving average is 629.82GBX and its 200-day moving average is 641.22GBX. The last stock close price is up 9.40% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 980,141 shares of the stock were exchanged, up from an average trading volume of 584,304

See Chart Below


BTG PLC has a 52 week low of 504.00GBX and a 52 week high of 739.50GBX with a P/E ratio of 44.97 The company’s market cap is currently 0 GBX.


BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing. The Interventional Medicine segment includes oncology, vascular and pulmonology. The segment's products include Beads, TheraSphere, EkoSonic, Varithena and PneumRx Coils for use in the treatment of liver tumors, blood clots, varicose veins and advanced emphysema. The Specialty Pharmaceuticals segment includes CroFab, DigiFab, Voraxaze and Vistogard products for use in the treatment of crotalid envenomation, digoxin toxicity, high-dose methotrexate toxicity and 5-fluorouracil toxicity. The Licensing segment includes Zytiga, Two-Part Hip Cup and Lemtrada products for use in the treatment of advanced prostate cancer, hip replacement and multiple sclerosis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.